Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan

Yusuke Takushima1,2, Ataru Igarashi1,3,*, Hiroshi Yoshihara1, Kohei Shitara4, and Toshihiko Doi5

1Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan, 2Medical Affairs Department, Taiho Pharmaceutical Co., Ltd, 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan, 3Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Kanagawa Japan, 4Department of Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan and 5Department of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan

*For reprints and all correspondence: Ataru Igarashi, Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail: atarui1@mac.com

Received 9 March 2021; Editorial Decision 21 May 2021; Accepted 26 May 2021

Abstract

Objective: Nivolumab and trifluridine/tipiracil have significantly improved the overall survival of patients with heavily pretreated metastatic gastric cancer in different placebo-controlled phase III trials. Accordingly, nivolumab and trifluridine/tipiracil have been approved and recommended for patients with heavily pretreated metastatic gastric cancer in Japan. The aim of this study was to assess the cost-effectiveness of trifluridine/tipiracil against nivolumab.

Methods: A partitioned survival model, which consisted of three health states, namely, ‘pre-progression,’ ‘post-progression,’ and ‘death,’ was constructed. Efficacy and safety data were derived from the TAGS and ATTRACTION-2 trials. Costs were estimated based on the standard clinical pathway and national insurance fee schedules. One-way and probabilistic sensitivity analyses were performed. The threshold value was set to JPY 7 500 000 (USD 68 182) for each quality-adjusted life-year.

Results: The expected median overall survival and progression-free survival were 5.59 and 1.99 months for trifluridine/tipiracil and 5.26 and 1.55 months for nivolumab, respectively. The quality-adjusted life-year and expected costs per patient were 0.4379 and JPY 2 054 625 (USD 18 678) for trifluridine/tipiracil and 0.5295 and JPY 5 018 148 (USD 45 620) for nivolumab, respectively. The expected median progression-free survival and overall survival were equivalent with trifluridine/tipiracil and nivolumab, whereas the expected quality-adjusted life-year with trifluridine/tipiracil was slightly lower than that with nivolumab. However, trifluridine/tipiracil reduced the total treatment cost by JPY 2 963 523 (USD 26 996) compared with that of nivolumab. The incremental cost-effectiveness ratio of nivolumab versus trifluridine/tipiracil was JPY 32 352 489 (USD 294 113) per quality-adjusted life-year gained.

Conclusions: Trifluridine/tipiracil was more cost-effective than nivolumab for patients with heavily pretreated metastatic gastric cancer.
Introduction

Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths (1). The expected outcomes are poor for patients with unresectable metastatic gastric cancer, and treatment is generally limited to palliative chemotherapy. Combination chemotherapy, consisting of fluoropyrimidine-based drugs (5-fluorouracil, S-1 or capecitabine) and platinum-based drugs (cisplatin or oxaliplatin), has been recommended as the first-line therapy strategy for metastatic gastric cancer by the Japanese Gastric Cancer Association (JGCA), the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (2–4). Furthermore, combination therapy with fluoropyrimidine-based drugs, platinum-based drugs and trastuzumab is used for human epidermal growth factor receptor 2 (HER2; also known as ERBB2)-positive metastatic gastric cancer (2–4). In case of failure of the first-line chemotherapy strategy, combination therapy with paclitaxel and ramucirumab has been recommended as a second-line treatment for metastatic gastric cancer (2–4). In case of failure of both first- and second-line treatments, no global standard third-line therapy strategy has been recommended for metastatic gastric cancer, and treatment methods vary among different countries.

Nivolumab, a fully human IgG4 monoclonal antibody inhibitor of programmed death-1, has significantly improved the overall survival (OS) of patients with heavily pretreated metastatic gastric cancer in the Asian phase III ATTRACTION-2 trial (5). Hence, nivolumab has been recommended by JGCA guidelines and is widely used in Japan to treat metastatic gastric cancer. The 2-year follow-up data of the ATTRACTION-2 trial were published in the proceedings of the ESMO 2018 Congress (6), and the median OS was reported to be 5.26 months [95% confidence interval (CI), 4.60–6.37 months] with nivolumab and 4.14 months (95% CI, 3.42–4.86 months) with placebo [hazard ratio (HR) = 0.62; 95% CI, 0.51–0.76; P < 0.0001].

Trifluridine/tipiracil (FTD/TPI, also known as TAS-102) is a novel oral cytotoxic chemotherapy combination consisting of a thymidine-based nucleoside analog (FTD) and a thymidine phosphoribylase inhibitor (TPI). FTD/TPI has a unique mechanism of action wherein FTD is incorporated into DNA, resulting in DNA dysfunction (7–9). After the efficacy and safety of the drug were established in the phase III RECURSE trial (10), FTD/TPI was approved in Japan, the European Union (EU), the USA and other countries as a treatment strategy for patients with metastatic colorectal cancer that is refractory to standard therapies. Furthermore, FTD/TPI has revealed a promising efficacy and acceptable tolerability in patients with heavily pretreated metastatic gastric cancer in the global phase III TAGS trial (11), with a median OS of 5.7 months (95% CI, 4.8–6.2 months) in the FTD/TPI group and 3.6 months (95% CI, 3.1–4.1 months) in the placebo group (HR = 0.69; 95% CI, 0.56–0.85; one-sided P = 0.000029). In 2019, FTD/TPI was approved in Japan, the US and the EU for patients with heavily pretreated metastatic gastric cancer and has recently been included in JGCA guidelines, with similar recommendations as those for nivolumab. Only nivolumab and FTD/TPI are listed at the same evidence level.

In addition to efficacy and safety, efficiency and cost-effectiveness have emerged as important factors that impact the choice of drug treatment, particularly for anticancer drugs. Governments, health care providers and the public have displayed an increasing interest in learning more about efficiency in resource allocation. In terms of the economic evaluation of FTD/TPI, several studies have assessed the cost-effectiveness of FTD/TPI treatment for patients with gastrointestinal cancer (12–15). However, few studies have focused on gastric cancer, and none has compared the cost-effectiveness of FTD/TPI and nivolumab. Therefore, in this study, we compared the cost-effectiveness of FTD/TPI and nivolumab for patients with heavily pretreated metastatic gastric cancer from the perspective of the Japanese public health care payer.

Materials and methods

Model structure

A partitioned survival model (PSM) was generated using TreeAge Pro 2018 R2.1 (TreeAge Software, Inc., Williamstown, MA, USA). PSMs are commonly used for the health–economic analysis of anticancer medications and submission of official documents for national health technology assessment agencies, such as the National Institute for Health and Care Excellence (NICE) in the UK (16). In the PSM used in this study, the following three health states were considered: ‘pre-progression,’ ‘post-progression,’ and ‘death.’ The PSM revealed the proportion of patients in each cycle, and the cost, life years and quality-adjusted life-years (QALYs) were estimated. The model structure is presented in Fig. 1.

Treatment protocol

Nivolumab was administered intravenously every 2 weeks, whereas FTD/TPI was administered orally on days 1–5 and 8–12 of each 4-week treatment cycle. Thus, for this analysis, 2 weeks were set as one cycle, and 52 weeks (26 cycles) were considered to be 1 year. The time horizon was set at 520 weeks (10 years). A 10-year period was considered sufficient for lifetime assessment; the likelihood that target patients or those with heavily pretreated metastatic gastric cancer would survive for 520 weeks or longer was considered to be low. In our analysis, death occurred in 99% of patients by 160 weeks on FTD/TPI therapy and by 192 weeks on nivolumab therapy.

Clinical estimates

Efficacy and safety data were derived from the TAGS and ATTRACTION-2 trials. The probability distribution was applied and estimated in accordance with the most recently published data on OS and progression-free survival (PFS) curves for the FTD/TPI group in the TAGS trial (11) and the nivolumab group in the ATTRACTION-2 trial (6). Superposition of the Weibull distribution was adopted for this analysis as the most appropriate distribution in accordance with the R-squared value and Akaike information criterion (AIC). The distribution of each curve was estimated on the basis of the OS and PFS curves using the Weibull distribution. The parameters of each distribution were set to ensure the most appropriate R-squared value and AIC figures as follows:

$$S(x) = w e^{-(x/a1)^{m1}} + (1 - w) e^{-(x/a2)^{m2}}$$
Figure 1. Model structure.

Table 1. Parameters estimated for each distribution

| Parameter                      | FTD/TPI          | Nivolumab        |
|--------------------------------|------------------|------------------|
| Overall survival               |                  |                  |
| $w$                            | 0.230855949      | 0.368655975      |
| $\eta_1$                       | 33.89876352      | 7.285138986      |
| $m_1$                          | 1.335055548      | 2.129129407      |
| $\eta_2$                       | 12.193089        | 28.1395343       |
| $m_2$                          | 1.373256081      | 1.164429921      |
| Progression-free survival      |                  |                  |
| $w$                            | 0.634034131      | 0.391491811      |
| $\eta_1$                       | 9.672317513      | 2.974408627      |
| $m_1$                          | 1.383143905      | 15.91853832      |
| $\eta_2$                       | 3.747731973      | 11.53140838      |
| $m_2$                          | 15.15906897      | 0.847673601      |

Our survival function is a linear combination of two Weibull distributions. Each Weibull distribution has two parameters: $\eta$ and $m$. $m$ ($>0$) is the shape parameter, which affects the shape of the distribution, whereas $\eta$ ($>0$) is the scale parameter, which stretches or shrinks the distribution. Weights of each distribution are defined as $w$ and $(1-w)$, whereas $0 \leq w \leq 1$.

Our survival function is a linear combination of two Weibull distributions. Each Weibull distribution has two parameters: $\eta$ and $m$. $m$ ($>0$) is the shape parameter, which affects the shape of the distribution, whereas $\eta$ ($>0$) is the scale parameter, which stretches or shrinks the distribution. Weights of each distribution are defined as $w$ and $(1-w)$, whereas $0 \leq w \leq 1$.

The estimated parameters for FTD/TPI and nivolumab are displayed in Table 1. To validate our model, the estimation was carried out using SAS software version 9.4 (SAS Institute, Inc., Cary, NC, USA). Similarly, OS and PFS distributions were observed for FTD/TPI and nivolumab (data not shown). Similar estimates were implemented for the placebo groups in the TAGS and ATTRACTION-2 trials, and similar results were obtained ($R^2 = 0.99967$). Therefore, FTD/TPI and nivolumab were comparable in this analysis without any statistical adjustment.

Quality of life score estimates

No quality of life (QoL) score data were collected in the TAGS and ATTRACTION-2 trials; thus, for this analysis, EQ-5D data collected in the INTEGRATE trial, a randomized, placebo-controlled phase II trial ofregorafenib for the treatment of metastatic gastric cancer (17,18), were derived. The patient population of the INTEGRATE trial had recurrent or metastatic disease that was refractory to two or fewer lines of chemotherapy (including prior treatment with fluoropyrimidine and platinum), similar to the population examined in our analysis. The pre- and post-progression QoL score were set at 0.73 and 0.69, respectively, based on the results of the INTEGRATE trial. As a decrease of QoL score owing to adverse events was not reported for Japanese patients, it was not considered in this analysis.

Cost estimates

The following direct medical costs were determined and considered in this analysis: costs of drugs, medications, imaging, treatment for adverse events, drugs used after treatment and end-of-life care (Table 2). The drug and imaging costs and medical care fees for the analysis were based on the prices in the national drug tariff and national medical care fee schedule as of 1 December 2018.
Table 2. Model parameters

| Parameter                       | Type of distribution | FTD/TPI  | Nivolumab | Range       |
|---------------------------------|----------------------|----------|-----------|-------------|
| Cost (JPY)                      |                      |          |           |             |
| Drug price (per 2 weeks)        | Gamma                | 99 969   | 410 580   | ±10%        |
| Adverse events                  | Gamma                | 17 183.4 | 6071.10   | ±25%        |
| Administration (first cycle)    |                      | 47 255.7 | 47 745.7  |             |
| Administration (after second cycle) |                  | 5180.00  | 10 660.00 |             |
| Post-treatment                  |                      | 410 580.00 | 199 938.00 |             |
| End-of-life                     | Gamma                | 1 120 000 |           | ±25%        |
| Imaging                         |                      | 15 200   |           |             |
| QoL score                       |                      |          |           |             |
| Pre-progression                 | Normal               | 0.73     |           | ±25%        |
| Post-progression                | Normal               | 0.69     |           | ±25%        |
| Others (%)                      | Triangular           | 25       |           | 0–61        |
| Discount rate                   |                      | 2        |           | 0–4         |

FTD/TPI, trifluridine/tipiracil; JPY, Japanese yen.

Table 3. Base-case results

| Parameter                        | FTD/TPI   | Nivolumab |
|----------------------------------|-----------|-----------|
| Cost/patient (JPY)               | 2 054 625 | 5 018 148 |
| ΔCost/patient (JPY)              | −2 963 523|           |
| QALY                             | 0.4379    | 0.5295    |
| ΔQALY                            | −0.0916   |           |
| ICER (Δcost/ΔQALY)               | 32 352 489|           |
| Median life-years (years)        | 0.47      | 0.44      |
| Median life-years (months)       | 5.59      | 5.26      |
| ΔMedian life-years (months)      | +0.33     |           |
| Median PFS (years)               | 0.17      | 0.13      |
| Median PFS (months)              | 1.99      | 1.55      |
| ΔMedian PFS (months)             | +0.44     |           |

FTD/TPI, trifluridine/tipiracil; ICER, incremental cost-effectiveness ratio; JPY, Japanese yen; PFS, progression-free survival; QALY, quality-adjusted life-year.

No confidential discount system has been implemented in Japan. Although drug prices are revised every 2 years, they are fixed in Japan. The willingness-to-pay (WTP) threshold (under which a drug is considered cost-effective) is JPY 7 500 000 (USD 68 182; exchange rate of USD 1 = JPY 110 as of December 2018) for an anticancer drug.

The cost of each drug was determined based on the following body parameters: height, 165 cm; weight, 70 kg and body surface area, 1.73 m². FTD/TPI was administered at a dose of 35 mg/m² twice daily on days 1–5 and 8–12 of each 28-day treatment cycle. The cost for the 4-week therapy was JPY 199 938 (USD 1818); thus, the cost for 2 weeks of treatment was JPY 99 969 (USD 909). Nivolumab was administered at 240 mg every 2 weeks and entailed a 2-week treatment cost of JPY 410 580 (USD 3733).

Not all patients with heavily pretreated metastatic gastric cancer received post-treatment chemotherapy. The post-treatment transition rate was set at 25% in accordance with the results of the TAGS trial. From a conservative perspective, as the cost of nivolumab was higher than that of FTD/TPI, the patients who received FTD/TPI received nivolumab as post-treatment, and the patients who received nivolumab received FTD/TPI as post-treatment. The treatment duration was further shortened in the post-treatment stage; therefore, we decided to implement only one cycle of chemotherapy.

Imaging analyses were conducted every 8 weeks in the TAGS trial and every 6 weeks in the ATTRACTION-2 trial. To ensure that the expenses did not differ between the groups, we decided to perform imaging tests every 8 weeks (based on the opinion of a medical expert) and to conduct these tests conservatively. In clinical practice, imaging tests are conducted when patients receive chemotherapy; however, in this study, the cost of imaging tests during post-treatment chemotherapy was not considered because post-treatment chemotherapy was set as one cycle.

The cost of supportive therapy for adverse events was determined based on the incidences of adverse events reported in the TAGS and ATTRACTION-2 trials. The adverse events analysed herein served to satisfy the following three criteria: (i) grade 3 or higher adverse events that occurred in the TAGS and ATTRACTION-2 trials, (ii) adverse events with an incidence of 2% or higher in the TAGS and ATTRACTION-2 trials and (iii) adverse events described in the package inserts of the drugs in Japan. The costs of supportive therapy for adverse events that satisfied these requirements were determined after a review by a medical expert. The expected costs of treatments with FTD/TPI and nivolumab were estimated to be JPY 17 183.4 (USD 156) and JPY 6071.1 (USD 55), respectively.

The cost of end-of-life care was set as JPY 1 120 000 (USD 10 182) based on the estimates used by the Ministry of Health, Labor and Welfare (19).
Figure 2. One-way sensitivity analysis. The tornado plot shows the incremental cost-effectiveness ratio for different model input parameters. Red bars represent an increase in value and blue bars represent a decrease in value. FTD/TPI, trifluridine/tipiracil; JPY, Japanese yen; OS, overall survival; PFS, progression-free survival.

Sensitivity analysis

A sensitivity analysis was conducted to overcome uncertainties and assumptions in the data sources. A one-way sensitivity analysis was carried out to investigate the effect of each parameter used in the analysis. The costs of FTD/TPI and nivolumab varied by ±10%, whereas the QoL score, cost of supportive therapy and cost of end-of-life care varied by ±25%. The post-treatment transition rate varied within a range of 0–61%, based on the overall results of the TAGS and ATTRACTION-2 trials and the results for the Japanese subgroups. The discount varied within a range of 0–4% in accordance with the Japanese guidelines of the Center for Outcomes Research and Economic Evaluation for Health (20). The η₁ and w parameters in S(x) varied by two standard deviations for OS and PFS. Gamma distribution was used for estimating the costs of the drugs, supportive therapy and end-of-life care, whereas normal distribution was used for estimating the QoL score, η₁ and w parameters, and post-treatment transition rate. The factors used in the one-way sensitivity analysis, except for the discount rate, were randomly changed in the probabilistic sensitivity analysis. The details of the factors are shown in Table 2. Furthermore, 10 000 Monte Carlo simulations were conducted.

Scenario analysis

In addition to nivolumab and FTD/TPI, irinotecan or docetaxel is used in patients with heavily pretreated metastatic gastric cancer in Japan. Therefore, a scenario analysis was carried out. During the post-treatment period, patients in the nivolumab arm were equally administered irinotecan, docetaxel or FTD/TPI and those in the FTD/TPI arm were administered irinotecan, docetaxel or nivolumab.

Results

Base-case results

The results of the base-case model are listed in Table 3. The expected median PFS was 1.99 and 1.55 months for FTD/TPI and nivolumab, respectively. The median OS was 5.59 and 5.26 months for FTD/TPI and nivolumab, respectively. The QALYs were 0.4379 and 0.5295 for FTD/TPI and nivolumab, respectively. The expected costs per patient were JPY 2 054 625 (USD 18 678) and JPY 5 018 148 (USD 45 620) for FTD/TPI and nivolumab, respectively, with a cost difference of JPY 2 963 523 (USD 26 941). The incremental cost-effectiveness ratio (ICER) of nivolumab versus FTD/TPI was JPY 32 352 489 (USD 294 113) per QALY gained [threshold value = JPY 7 500 000 (USD 68 182)].

Sensitivity analysis

The results of the one-way sensitivity analysis are expressed as a tornado diagram in Fig. 2. The parameters affected by the ICER were ‘η₁-OS-nivolumab,’ ‘η₁-OS-FTD/TPI,’ ‘w-OS-FTD/TPI,’ pre-progression QoL score, ‘η₁-OS-nivolumab’ and the cost of nivolumab. The upper and lower limits of the ICER when each parameter was varied were JPY 5 624 672 (USD 51 191) and JPY 5 018 148 (USD 45 620), respectively. The results of the probabilistic sensitivity analyses are summarized in Fig. 3. The results of the cost-effectiveness acceptability curve indicated that the probability that the ICER for nivolumab versus FTD/TPI would fall below JPY 7 500 000 (USD 68 182)/QALY was 0%. The threshold for the ICER to reverse the cost-effectiveness of nivolumab and FTD/TPI was approximately JPY 32 500 000 (USD 295 453)/QALY.
Figure 3. Probabilistic sensitivity analysis. (A) Scatter plot with 10,000 Monte Carlo simulations in the cost-effectiveness plane. (B) Cost-effectiveness acceptability curve representing the probability of the incremental cost-effectiveness ratio. FTD/TPI, trifluridine/tipiracil; JPY, Japanese yen; QALY, quality-adjusted life-year; WTP, willingness to pay.

Scenario analysis
In the scenario analysis, the case changed the post-treatment and the expected costs per patient were JPY 1,986,721 (USD 18,061) and JPY 4,990,329 (USD 45,367) for FTD/TPI and nivolumab, respectively, with a difference of JPY 3,003,608 (USD 27,306). The ICER of nivolumab versus FTD/TPI was JPY 32,790,090 (USD 298,092)/QALY [threshold value = JPY 7,500,000 (USD 68,182)].

Discussion
Nivolumab and FTD/TPI both revealed promising efficacy and tolerable safety profiles in patients with heavily pretreated metastatic gastric cancer. However, the cost-effectiveness of each drug has remained unclear. To our knowledge, our study is the first cost-effectiveness analysis of FTD/TPI versus nivolumab for patients with heavily pretreated metastatic gastric cancer. From the perspective of the Japanese public health care payer, FTD/TPI is more cost-effective than nivolumab for patients with heavily pretreated metastatic gastric cancer.

A cost-effectiveness evaluation system, similar to the systems used in the UK and other countries, was introduced in Japan in April 2019. Unlike in other countries, the system in Japan is used to adjust prices rather than determine the reimbursement of drugs and medical devices. This system revealed the stepwise price adjustments of the ICER value at JPY 5,000,000 (USD 45,455), JPY 7,500,000 (USD 68,182) and JPY 10,000,000 (USD 90,909) (20). In particular, the ICER values of anticancer drugs underwent the stepwise price adjustments at JPY 7,500,000 (USD 68,182), JPY 11,250,000 (USD 102,273) and JPY 15,000,000 (USD 136,364). In this study, we determined the expected median PFS and expected median OS, which were 1.99 and 5.59 months for FTD/TPI and 1.55 and 5.26 months for nivolumab, respectively. The median PFS and median OS were similar in both treatment groups. Compared with that for nivolumab,
the expected QALY for FTD/TPI was lower by 0.0916, and the expected cost was lower by approximately JPY 3,000,000 (USD 27,275). This slight difference in the expected QALY may have been due to the presence of long-term survivors in the nivolumab group in the ATTRACTION-2 trial.

Considering that the expected QALY was higher in the nivolumab group than in the FTD/TPI group, we determined the ICER of nivolumab to FTD/TPI. A single technology appraisal of cladribine for treating patients with relapsing–remitting multiple sclerosis has suggested that a new drug that is less effective and less costly than an existing drug is considered cost-effective if the ICER generated is above the level considered acceptable (21); the reduced efficacy of a new drug relative to its competitor has been previously reported in the UK during NICE technology assessment. Per this recommendation, FTD/TPI can be considered cost-effective compared to nivolumab. The expected median PFS and OS were equivalent between the FTD/TPI and nivolumab groups, whereas the QALY for FTD/TPI was slightly lower (by 0.0916) than that for nivolumab; however, the cost was greatly reduced for FTD/TPI. Furthermore, the sensitivity analysis revealed that nivolumab was less likely to be cost-effective than FTD/TPI. The probability of nivolumab being cost-effective relative to FTD/TPI (ICER below JPY 7,500,000 (USD 68,182)) was 0%. Nivolumab would only be more cost-effective than FTD/TPI if WTP exceeded approximately JPY 32,500,000 (USD 295,455)/QALY.

This study has some limitations. First, the study used an indirect comparison method. Because there were no head-to-head randomized controlled trials for comparison between FTD/TPI and nivolumab, the efficacy and safety data were derived from individual trials. However, the sensitivity analysis revealed similar results for varying efficacy parameters; thus, it was unlikely that the indirect comparison affected the results. Furthermore, the estimated median PFS and OS were similar to the actual median PFS and OS in the TAGS and ATTRACTION-2 trials. Second, because EQ-5D data were not collected in the TAGS and ATTRACTION-2 trials, the QoL score was derived from the INTEGRATE trial. The INTEGRATE trial has a close patient background to the TAGS and ATTRACTION-2 trials. However, there were some differences, such as in terms of treatment line and participating countries. For example, all patients received two or more lines of chemotherapy in the TAGS and ATTRACTION-2 trials, whereas 58% of patients received two or more lines of chemotherapy in the INTEGRATE trial (17); the derived QoL score might be better than the actual QoL score of patients who received two or more lines of chemotherapy. Moreover, the INTEGRATE trial was conducted in Australia, New Zealand, South Korea and Canada, in other words, no Japanese patients were enrolled in the INTEGRATE trial. However, from a clinical perspective, such as an incidence of an adverse event, it is unlikely that FTD/TPI and nivolumab would show a significant difference in QoL score. It may be interesting to conduct an analysis using EQ-5D data from post-marketing surveillance of each drug. Third, the costs were based on assumptions rather than on actual figures; however, the assumptions were based on the treatment policies adopted in real-world clinical practice. Therefore, at the very least, it can be expected that the results did not favour one group over the other. Moreover, because the sensitivity analysis revealed that the costs of the drugs did not greatly affect the ICER, the assumptions were not considered a problem. Finally, as costs and insurance systems vary by country, the applicability of our results to other countries is limited. Our results would be most helpful to clinicians and payers in countries in which nivolumab is reimbursed for the treatment of metastatic gastric cancer.

In addition to the efficacy and safety, our cost-effectiveness analysis showed the additional value of FTD/TPI. The efficiency data of FTD/TPI, produced by our analysis, could be somewhat helpful for decision makers, such as clinicians and payers. In conclusion, from the perspective of the Japanese public health care payer, FTD/TPI was shown to be more cost-effective than nivolumab for patients with heavily pretreated gastric cancer.

Acknowledgements
The authors would like to thank Editage (www.editage.jp) for English language editing.

Author contributions
Y.T., A.I. and H.Y. designed the study, collected and analysed the data, and wrote the manuscript. S.K. and T.D. interpreted the data. All authors were involved in the development, review and approval of the final version of the manuscript.

Funding
This work was supported by Taiho Pharmaceutical Co., Ltd.

Conflict of interest
Yusuke Takushima is an employee of Taiho Pharmaceutical Co., Ltd. Ataru Igarashi received the following financial support: research funding from Taiho Pharmaceutical while conducting this study; grants and personal fees from Pfizer Japan, Terumo and Takeda Pharmaceutical; grants from Gilead Sciences, Intuitive Surgical, Boston Scientific Japan, Becton Dickinson and Company, Milliman, Fujifilm and CSL Behring Japan; and personal fees from Chugai Pharmaceutical, Astellas Pharma, Sanofi Japan, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Novartis Pharma Japan, Eisai, AbbVie, Sumitomo Dainippon Pharma, Ayumi Pharmaceutical, Medilead, Novo Nordisk Japan, Taiho Pharmaceutical and Otsuka Pharmaceutical. Hiroshi Yoshihara declared no conflicts of interest. Kohei Shitara received the paid consulting or advisory roles for Astellas Pharma, Lilly, Bristol-Myers Squibb, Takeda Pharmaceutical, Pfizer, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Novartis, AbbVie, GlaxoSmithKline, Daichi Sankyo, Amgen and Boehringer Ingelheim; honoraria from Novartis Pharma, AbbVie and Yakult; and research funding from Astellas Pharma, Lilly, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Daichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Medi Science and Eisai. Toshihiko Doi received grants and personal fees from MSD, Daichishi Sankyo, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Novartis, Janssen, Boehringer Ingelheim, Bristol-Myers Squibb and AbbVie; grants from Lilly, Merck Serono, Pfizer, Quintiles and Eisai; and personal fees from Amgen, Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer, Rakuten Medical, Ono Pharmaceutical, Astellas Pharma, Oncolys BioPharma and Otsuka Pharmaceutical.
References
1. Stomach, Globocan 2018 Lyon: Global Cancer Observatory. 2019 http://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf (25 April 2019, date last accessed).
2. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24:1–21.
3. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v38–49.
4. Gastric cancer (version 1. 2019). Plymouth meeting; national comprehensive cancer network; 2019. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. (25 April 2019, date last accessed).
5. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461–71.
6. Satoh T, Chen LT, Kang YK, et al. A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): two-years update data. Ann Oncol 2018;29:viii206.
7. Emura T, Nakagawa F, Fujioka A, et al. An optimal dosing schedule for a novel combination antimitabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 2004;13:249–55.
8. Muralaksmi Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 2000;17:277–83.
9. Tanaka N, Sakamoto K, Okabe H, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 2014;32:2319–26.
10. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015;372:1909–19.
11. Shihara K, Doi T, Dworkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19:1437–48.
12. Kimura M, Usami E, Iwai M, Go M, Teramachi H, Yoshimura T. Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer. Mol Clin Oncol 2016;5:635–40.
13. Bullement A, Underhill S, Foucheray R, Hartsell AJ. Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic colorectal cancer in England and Wales. Clin Colorectal Cancer 2018;17:e143–51.
14. Cho SK, Hay JW, Barzi A. Cost-effectiveness analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer in the United States. Clin Colorectal Cancer 2018;17:e751–61.
15. Zhou K, Zhou J, Zhang M, Liao W, Li Q. Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. Clin Transl Oncol 2020;22:337–43.
16. Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU Technical Support Document 19. Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. Sheffield (UK): NICE Decision Support Unit; 2017. http://nicedsu.org.uk/wp-content/uploads/2017/06/Partitioned-Survival-Analysis-final-report.pdf (25 April 2019, date last accessed).
17. Pavlakis N, Sjoquist KM, Martin AJ, et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol 2016;34:2728–35.
18. Martin AJ, Gibbs E, Sjoquist K, et al. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer 2018;21:473–80.
19. Japanese Ministry of Health, Labour and Welfare. 2007. https://www.mhlw.go.jp/shingi/2007/03/dl/s0322-11a.pdf (25 April 2019, date last accessed).
20. Full Scale Introduction of Cost-Effectiveness Evaluations in Japan. Tokyo: Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare (MHLW); 2019. https://c2h.niph.go.jp/tools/system/overview_en.pdf (25 April 2019, date last accessed).
21. Cladribine Tablets for Treating Relapsing–Remitting Multiple Sclerosis. London: National Institute for Health and Care Excellence; 2017. https://www.nice.org.uk/guidance/ta493 (25 April 2019, date last accessed).